title: [Chemotherapy of chronic myelocytic leukemia. Status of the German Multicenter Study on busulfan versus hydroxyurea versus alpha interferon, October 1897].
abstract: For palliative therapy during the chronic phase of CML busulfan has proved to be the drug of choice. During the past years hydroxyurea and also interferon-alpha have gained increasing significance since they might prolong the duration of the chronic phase. In a multicenter study it is being determined, whether the use of hydroxyurea or of interferon-alpha instead of busulfan prolongs the duration of the chronic phase of Philadelphia-positive CML. Additional goals are the examination, whether the types of disease evolution and the terminal phases differ between the treatment groups, and the prospective recognition of prognostic criteria for the duration of the chronic phase of CML. By November 26, 1987, 321 CML-patients had been randomized, 147 for busulfan, 149 for hydroxyurea and 25 for interferon-alpha. The average age is about 50 years. 59 patients reached the end of the chronic phase, 55 died. The mean observation time of all patients is 1.34 years. At present no significant difference in survival is recognizable between the busulfan and hydroxyurea groups. Fewer adverse effects have been observed in the hydroxyurea group. Philadelphia chromosome-negative patients show a higher average age and tend to have lower white blood cell and platelet counts. The number of patients having received interferon-alpha is still too small to allow evaluation. This report intends to document organization and progress of this study which to our knowledge is, at present, the largest ongoing prospective multicenter study on the therapy of CML.
authors.affiliation: Medizinische Poliklinik der Universität München.
authors.forename: R
authors.initials: R
authors.lastname: Hehlmann
authors.forename: B
authors.initials: B
authors.lastname: Anger
authors.forename: D
authors.initials: D
authors.lastname: Messerer
authors.forename: R
authors.initials: R
authors.lastname: Zankovich
authors.forename: L
authors.initials: L
authors.lastname: Bergmann
authors.forename: H J
authors.initials: HJ
authors.lastname: Kolb
authors.forename: P
authors.initials: P
authors.lastname: Meyer
authors.forename: U
authors.initials: U
authors.lastname: Essers
authors.forename: U
authors.initials: U
authors.lastname: Queisser
authors.forename: H
authors.initials: H
authors.lastname: Vaupel
mesh_terms: D002066:Busulfan / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005860:Germany, West; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D007370:Interferon Type I / Q000627:therapeutic use*; D007951:Leukemia, Myeloid / Q000628:therapy*; D010677:Philadelphia Chromosome; D011379:Prognosis; D011897:Random Allocation
chemical_list: D007370:Interferon Type I; D002066:Busulfan; D006918:Hydroxyurea
vernacular_title: Chemotherapie der CML. Stand der deutschen Multicenter-Studie Busulfan versus Hydroxyurea versus Interferon-alpha, Oktober 1987.